World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
59
Citations
12116
World Ranking
12566
National Ranking
5374

Research.com Recognitions

  • 1981 - Fellow of the American Association for the Advancement of Science (AAAS)
  • 1967 - Member of the National Academy of Sciences

Overview

Robert L. Metcalf was affiliated with the University of Illinois at Urbana-Champaign in the United States. Their research focused primarily on Medicine, with a specialization in Oncology, Surgery, and Otorhinolaryngology, among other subfields.

The scientist contributed extensively to the study of cancer, particularly in areas related to cancer immunotherapy, biomarkers, and the treatment and diagnosis of head and neck cancer as well as salivary gland tumors. Additional topics in their work included colorectal and anal carcinomas, cancer diagnosis and treatment methods, lung cancer treatments, mutations, and immune response mechanisms.

Frequently, Robert L. Metcalf collaborated with the following coauthors:

  • Simon Laban
  • Ainara Soria Rivas
  • Frédéric Triebel
  • Kevin J. Harrington
  • J. Christian

Their research outputs appeared in various scholarly venues, with multiple publications in:

  • Annals of Oncology
  • Clinical Cancer Research
  • Regular and Young Investigator Award Abstracts
  • Immuno-Oncology Technology
  • ESMO Open

Notable recent papers authored or coauthored by Robert L. Metcalf include:

  • "INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma" (2025, Clinical Cancer Research)
  • "675 TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma" (2022, Regular and Young Investigator Award Abstracts)
  • "LBA35 Primary results from TACTI-003: A randomized phase IIb trial comparing eftilagimod alpha (soluble LAG-3) plus pembrolizumab versus pembrolizumab alone in first-line recurrent or metastatic head and neck squamous cell carcinoma with CPS ≥1" (2024, Annals of Oncology)
  • "VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study" (2024, Annals of Oncology)
  • "870P POPPY: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients of performance status 2 with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC)" (2024, Annals of Oncology)

Throughout their career, Robert L. Metcalf focused their work on advancing the understanding and treatment of cancer through clinical trials and immunotherapy research.

Recognitions awarded to them included being named a Fellow of the American Association for the Advancement of Science (AAAS) in 1981 and becoming a Member of the National Academy of Sciences in 1967.

Best Publications

  • Changing Role of Insecticides in Crop Protection

    R. L. Metcalf

  • Destructive and useful insects

    C. L. Metcalf;W. P. Flint;R. L. Metcalf

  • Comparative metabolism of methoxychlor, methiochlor, and DDT in mouse, insects, and in a model ecosystem.

    Kapoor Ip;Metcalf Rl;Nystrom Rf;Sangha Gk

  • Plant kairomones in insect ecology and control

    Robert Lee Metcalf;Esther R. Metcalf

  • Plant volatiles as insect attractants

    Robert L. Metcalf;Marcos Kogan

  • Model ecosystem for the evaluation of pesticide biodegradability and ecological magnification

    Robert L. Metcalf;Gurcharan K. Sangha;Inder P. Kapoor

  • Mode of Action of Insecticide Synergists

    Robert L. Metcalf

  • A century of DDT.

    Robert L. Metcalf

  • Chemical ecology of Dacinae fruit flies (Diptera: Tephritidae).

    Robert L. Metcalf

  • Advances in pest control research

    Robert Lee Metcalf

  • Cucurbitacins : Plant-derived defense compounds for diabroticites (Coleoptera: Chrysomelidae).

    J E Ferguson;R L Metcalf

  • Organic insecticides : their chemistry and mode of action

    Robert Lee Metcalf

  • Environmental fate and biodegradability of benzene derivatives as studied in a model aquatic ecosystem.

    Po-Yung Lu;Robert L. Metcalf

  • Cucurbitacin Contents and Diabroticite (Coleoptera: Chrysomelidae) Feeding upon Cucurbita spp.

    Robert L. Metcalf;A. M. Rhodes;Robert A. Metcalf;Jane Ferguson

  • Extractable hydrocarbons and kin recognition in honeybee (Apis mellifera L.).

    Robert E. Page;Robert A. Metcalf;Robert L. Metcalf;Eric H. Erickson

  • Metabolism of 2,2-dimethyl-2,3-dihydrobenzofuran-7-N-methylcarbamate (Furadan) in plants, insects, and mamals

    Robert L. Metcalf;T. Roy. Fukuto;Crystal. Collins;Kathleen. Borck

  • Structure-activity relationships for insecticidal carbamates.

    Robert L. Metcalf

  • Model ecosystem studies of the environmental fate of six organochlorine pesticides.

    Robert L. Metcalf;Inder P. Kapoor;Po-Yung Lu;Carter K. Schuth

  • Laboratory model ecosystem studies of the degradation and fate of radiolabeled tri-, tetra-, and pentachlorobiphenyl compared with DDE.

    Robert L. Metcalf;Robert L. Metcalf;James R. Sanborn;James R. Sanborn;Po-Yung Lu;Po-Yung Lu;Donald Nye;Donald Nye

  • Degradation and environmental fate of 1-(2,6-difluorobenzoyl)-3-(4-chlorophenyl)urea

    Robert L. Metcalf;Po-Yung. Lu;Stephen. Bowlus

Frequent Co-Authors

Gregory S. Whitt
Gregory S. Whitt University of Illinois at Urbana-Champaign
John A. Katzenellenbogen
John A. Katzenellenbogen University of Illinois at Urbana-Champaign
Robert E. Page
Robert E. Page University of California, Davis

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Robert L. Metcalf